ESMO 2026: Bladder and kidney cancer roundup
Prof Jens Bedke talks to ecancer at ESMO 2026 about results from the phase III KEYNOTE-866 trial, which evaluated perioperative pembrolizumab alongside neoadjuvant gemcitabine and cisplatin chemotherapy in patients with muscle-invasive bladder cancer (MIBC).
The study randomised 907 patients to receive pembrolizumab or placebo alongside chemotherapy, followed by radical cystectomy and adjuvant treatment.
After a median follow-up of 60.9 months, pembrolizumab did not significantly improve event-free survival (HR 0.88; P = 0.1366) or demonstrate an overall survival benefit (HR 1.00).
Although pathological complete response rates were higher with pembrolizumab (44.4% versus 35.8%), the primary endpoint was not met.
The findings suggest that adding perioperative pembrolizumab to cisplatin-based chemotherapy and surgery does not provide a significant clinical benefit in this patient population.
ESMO 2026: Bladder and kidney cancer roundup
ESMO 2026: Prostate cancer roundup
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety
Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer
AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA
Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery
Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension
ASCO 2025: Importance of early testing in metastatic prostate cancer
Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer